Appeal 2007-1070
Application 09/467,901
to magnetic particles (“antibody directed against the [IgE] antibody”) to
form a first complex (Johansen, col. 3, ll. 37-42; col. 5, ll. 50-60; Answer 4).
4. The label (“chemiluminescent acridinium compound”) is added to the
first complex to form a second complex (Johansen, col. 3, ll. 43-46; Answer
4).
5. The second complex is separated from the liquid phase and the label is
detected (Johansen, col. 3, ll. 47-51; Answer 4).
6. Example 2 describes detection and quantification of a specific IgE
according to this method (Johansen, cols. 8-9).
7. Johansen’s Fig. 1 illustrates the assay steps.
8. The correspondence between the steps recited in instant claim 1 and
Johansen’s specific IgE assay is shown below.
Claim 1 Johansen’s Fig. 1
9. Johansen’s assay meets the limitations of steps (a)-(d) of claim 1, but
does not describe using an IgE receptor which is “CD23 (FcεRII) and/or
FcεR1” as recited in step (b). (Answer 5).
6
Page: Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Next
Last modified: September 9, 2013